Find out now if you qualify. Time is limited to file a claim. You may be entitled to compensation. Fill out the form below to see if you qualify.
Semaglutide Patients At Risk
Information submitted will be transmitted to a law firm. This communication is intended to be an attorney-client communication for purposes of evaluating your claim and will be kept confidential by the law firm. The communication does not create an attorney-client relationship and no relationship is formed until a fee agreement is signed by you and the law firm. I also have read and agree to your Privacy Policy
File Your Claim Now
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES
We are here to listen and help answer all your questions. Contact us today for a Free Claim Review by filling out the form above.
Additional Studies
If you or a family member suffered from NAION or sudden vision loss after taking Ozempic or Wegovy (semaglutide). Our experienced legal team will handle every aspect of the process, including gathering medical records and expert evaluations. We work on a contingency basis, meaning you pay nothing unless we win your case. Contact us today to find out if you qualify. Significant compensation may be available.
Seek Justice Today
Maryland Juvenile Detention
Abuse Claim Help
Jeff Brandow
Sexual Abuse
Claim Help
File Your Claim Now
If you were prescribed Ozempic or Wegovy (semaglutide) and later experienced sudden vision loss, you may qualify to file a claim. Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious optic nerve injury that can cause permanent, often painless loss of vision in one or both eyes. Recent peer-reviewed studies and European drug-safety regulators have identified NAION as a rare but documented risk with semaglutide. The pharmaceutical companies responsible for these drugs have failed to warn healthcare professionals and patients of these potential but serious side effects.
A significant cohort study published in JAMA Ophthalmology analyzed data from over 16,000 patients and found that those prescribed semaglutide had a higher incidence of developing NAION compared to those on other medications. Specifically, in the diabetes group, 17 out of 200 patients on semaglutide developed NAION, a rate four times higher than those not on the medication. In the obesity group, 20 out of 361 patients on semaglutide developed the condition, a rate seven times higher.
"Trust our experienced team to handle your claim with care and commitment. Contact us today for reliable legal support."
Our dedicated team will fight for your rights and compensation. Confidentiality, Safety, & Justice are our top priorities
How to Qualify for a Depo-Provera Claim:
Use of Depo-Provera
Diagnosis of Brain Tumor
Document Evidence
Submit The Form Above
Depo-Provera is an injectable birth control containing the synthetic hormone medroxyprogesterone acetate, is linked to an increased risk of meningioma, a rare brain tumor. This risk was not adequately disclosed to consumers or medical professionals. Studies, including those published in the Journal of the American Medical Association (JAMA), have shown that long-term use of Depo-Provera significantly raises the risk of developing meningiomas.
Claims against Pfizer, Inc., the drug’s manufacturer, alleges that the company knew or should have known about the increased risk of meningiomas—brain tumors that can cause severe neurological symptoms—especially with prolonged use. The claims state that Pfizer failed to adequately warn doctors and patients, rushed the drug to market without sufficient long-term studies, and prioritized profits over safety.
Due to the rising number of claims against Pfizer regarding Depo-Provera and brain tumors have been consolidated into multidistrict litigation (MDL) in federal court. Affected individuals may seek compensation for medical expenses, long-term care, and other damages, with the potential for federal court consolidation of cases.
NAION Claim Help
Justice & Compensation - Start Here
It’s important to work closely with your healthcare provider on your treatment plan, but you should also explore your legal options. Anyone who was prescribed Ozempic or Wegovy (semaglutide) and experienced complications such as NAION, please fill out the form above.
These findings underscore the importance of healthcare professionals being aware of the potential risk of NAION when prescribing semaglutide and monitoring patients accordingly.
NAION Symptoms:
Sudden vision loss – Often in one eye, typically occurring within hours.
Blurry or dim vision – Affected vision may appear cloudy or foggy.
Visual field defects – Loss of vision in specific areas, such as peripheral vision or central vision.
Optic disc swelling – Inflammation or swelling of the optic nerve visible during an eye exam.
Painless vision loss – The vision loss occurs without any pain or discomfort.
Color vision changes – Colors may appear washed out or less vibrant in the affected eye.
Visual disturbances – Some people may experience visual distortions or seeing shadows.
Reduction in contrast sensitivity – Difficulty distinguishing between subtle differences in shades of light and dark.
The European Medicines Agency (EMA) has also reviewed the potential association between semaglutide and NAION. Their Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION is a side effect of semaglutide medicines—Ozempic and Wegovy—potentially affecting up to 1 in 10,000 users. As a result, the EMA recommended updating the product information for these medicines to include NAION specific warnings. Additionally, the World Health Organization (WHO) has issued a safety alert regarding the use of semaglutide and the risk of NAION.
